BioTools Innovator

Limula develops an automated cell therapy manufacturing platform that combines bioreactor and centrifuge capabilities into a single device, supported by hardware, software, and consumables. The platform enables scalable, decentralized production of cell therapies by bringing manufacturing closer to patients and supporting multiple cell types. It automates complex processing steps within a closed, modular system, allowing biotech and pharmaceutical companies to move from open, manual methods to automated operations, improving efficiency, safety, and accessibility of personalized treatments.

Briefcase Biotec develops KiloBaser, a Nespresso machine of DNA synthesis - enabling cutting edge research without detours. KiloBaser is a device for printing short synthetic DNA sequences. It enables individual scientists to easily produce the DNA they need on their desktops, while speeding up production of the basics for all genetic engineering and synthetic biology research and development. Headquartered in Graz, Steiermark, KiloBaser was founded in 2013 by Martin Jost and Alexander Murer.

BacStitch DNA is a DNA assembly revolution that accelerates protein, pathway, and cellular engineering.

BioRaptor is developing an innovative operating system specifically for biotech and biopharma companies. This platform harnesses artificial intelligence to ingest and harmonize data from diverse sources, empowering scientists to leverage scientific information effectively. By enabling the design of improved experiments and facilitating insightful analysis of experimental outcomes, BioRaptor supports data-driven decision-making within the industry. The company's focus is on enhancing productivity and providing valuable insights that can accelerate research and development processes in the biotech sector.

Atomnaut is a developer of advanced microscopy technology, specializing in a 3D atomic resolution microscope. This innovative device employs atom microscope by projection (AMP) technology, which allows for the precise imaging, analysis, sequencing, and design of atoms in three-dimensional space. Atomnaut's offerings include a variety of materials critical for various industries, such as silicon transistors, high-strength steels, nanowires, quantum dots, tungsten alloys for fusion and aerospace applications, as well as nanostructured light and strong aluminum alloys. Through its cutting-edge technology, the company enables scientists to identify and determine the atomic structure of materials, contributing to advancements in materials engineering and design.

TeraCyte Analytics specializes in predicting human medication response. It achieves this by analyzing single-cell dynamics, providing pharmaceutical researchers with valuable insights to understand and forecast cellular reactions to new drugs or perturbations. This enables informed decision-making in drug development and treatment strategies.

Argome is a smart nanoparticle platform that allows for a uniform next-generation multiomic approach.

Scribe Biosciences specializes in developing single-cell analysis tools for both clinical and research applications. The company utilizes Printed Droplet Microfluidics (PDM), a technology that allows for precise manipulation of fluids at the picoliter scale. This system employs fluorescence-activated microfluidic droplet sorting and a specialized substrate to handle individual cells and fluid samples with high throughput, enabling detailed studies in areas such as infectious diseases and cancer research.

BennuBio, Inc. is a technology company based in Albuquerque, New Mexico, that specializes in developing advanced flow cytometry equipment for cell analysis. Founded in 2018, BennuBio focuses on creating instruments capable of sorting and analyzing cells for rare cell applications, which include monitoring blood cells, detecting biomarkers, and facilitating drug discovery. Its flagship product, The Velocyt, enables users to detect rare events such as activated T cells and circulating tumor cells, making it valuable for personalized medicine. The company also offers spheroid generation systems and high-volume sorting systems, along with technical support and applications assistance. By allowing analysis across a wide range of particle sizes and sample volumes, BennuBio aims to enhance the capabilities of healthcare professionals in immuno-oncology treatment and diagnostics.

Switchback Systems is an early-stage startup founded in 2019 by Mary Noe, specializing in the development of a highly scalable DNA synthesis platform. The company aims to revolutionize nucleic acid applications by significantly reducing the time, cost, and waste associated with DNA synthesis. Its innovative technologies leverage cell structure as a medium for data storage, enabling the creation of a benchtop DNA printer that provides on-demand biological discovery for laboratories across the healthcare industry. Through these advancements, Switchback Systems seeks to enhance the efficiency and accessibility of genetic research and development.

Aureka Biotechnologies is an innovative biotechnology company focused on transforming the pharmaceutical industry to enhance access to treatments. The firm has developed a therapeutic discovery platform that utilizes advanced machine learning and artificial intelligence technologies to streamline the drug design process. By digitalizing therapeutic design at scale, Aureka Biotechnologies aims to identify and create potential drug candidates more efficiently, thereby significantly reducing both the cost and time associated with developing new therapies. The company's mission is to democratize the pharmaceutical sector, making it easier to address various health challenges and improve patient outcomes.

CRISPRQC develops an analytics platform that enhances the efficiency and effectiveness of CRISPR gene editing. This platform is built around the CRISPR-Chip, a unique device that directly measures CRISPR activity. By simulating the gene editing process prior to cell introduction, CRISPRQC provides essential data and insights that are crucial for quality control and maximizing the potential of CRISPR technology. The platform empowers scientists to increase editing efficiency and formulate strategies for improved outcomes at the cellular level, ultimately accelerating the development of CRISPR-based products.

ReelReactor specializes in developing continuous reactor technologies aimed at enhancing throughput, efficiency, and quality of various chemical, pharmaceutical, and biological products and therapies. Its innovative technology has the potential to reduce costs, improve product consistency, and make therapies more accessible.

mk2 Biotechnologies uses a synthesis process to design, synthesize, and research peptides and proteins. Their process allows the scalable and production of purity peptides and proteins for a range of applications.

Aopia Biosciences is a biotechnology company dedicated to advancing bioengineering solutions and technologies for biomedical research, diagnostics, and therapeutic applications. The company specializes in ultra-high sensitivity biomarker detection, which facilitates early disease diagnosis and treatment monitoring. Aopia's innovative platform supports researchers in the exploration of extracellular vesicles (EVs) and exosomes, enhancing the understanding and potential treatment of various medical conditions. Through its focus on cutting-edge technologies, Aopia Biosciences aims to improve outcomes in healthcare by providing tools that enable precise and effective medical interventions.

Limula develops an automated cell therapy manufacturing platform that combines bioreactor and centrifuge capabilities into a single device, supported by hardware, software, and consumables. The platform enables scalable, decentralized production of cell therapies by bringing manufacturing closer to patients and supporting multiple cell types. It automates complex processing steps within a closed, modular system, allowing biotech and pharmaceutical companies to move from open, manual methods to automated operations, improving efficiency, safety, and accessibility of personalized treatments.

Indee Labs develops hardware and platform technologies for gene delivery to immune cells, with the aim of enabling the rapid development and scalable manufacture of gene-modified cell therapies, including CAR-T cells. The company focuses on non-viral delivery methods to introduce small molecules, nucleic acids, proteins, and gene-editing complexes into immune cells, supporting biopharmaceutical research and manufacturing while maintaining high cell viability and function. Its technology has progressed with collaboration from national facilities and through participation in biotech incubators and accelerators. Indee Labs maintains an international footprint, with an office in Sydney and lab space in Berkeley, reflecting its cross-regional development and manufacturing focus.

PAK BioSolutions specializes in the manufacture of biopharmaceuticals, focusing on the growing demand for automation equipment and consumables. The company offers a range of products, including automated systems and single-use flow kits, designed for end-to-end continuous manufacturing processes in both laboratory and GMP facilities. By implementing continuous processes, PAK BioSolutions aims to enhance productivity, reduce capital costs, and minimize facility footprints for its clients. Additionally, the company provides consulting services to support the effective integration of its solutions into existing operations.

Andson Biotech specializes in the development of innovative Process Analytical Technologies (PATs) tailored for cell-based bioprocesses in advanced biomanufacturing. The company has created a novel secretome analysis system that enhances and streamlines traditional analytical measurements typically conducted through mass spectrometry workflows. By utilizing its core technologies, Andson Biotech accelerates the drug discovery process, enabling the development of assays that expedite the path to market for advanced therapies. Their offerings include recombinant proteins, monoclonal antibodies, and vaccines, aimed at providing healthcare professionals with essential biopharmaceutical products.

Clara Biotech is a biotechnology company that focuses on the isolation and purification of exosomes from small fluid samples, facilitating liquid biopsy applications for the early detection of diseases such as cancer and Alzheimer's Disease. The company's innovative platform overcomes traditional challenges in exosome harvesting, which typically relies on a lengthy ultra-centrifugation process. Clara Biotech's technology allows for the extraction of pure, viable exosomes from any biofluid source, enhancing the purity and potency of these cellular markers. In addition to advancing diagnostic capabilities, the platform also supports the development of precision medicine by enabling targeted drug delivery directly to specific cells. By bridging the gap between research and patient care, Clara Biotech positions itself at the forefront of exosome-related breakthroughs in the biopharmaceutical field.

Kolibri specializes in developing innovative bioreactors that significantly enhance cell culture yields while reducing production costs. Their proprietary platform, combining cutting-edge acoustics and biology techniques, aims to make cell and gene therapies more accessible and affordable.

Atom Bioworks develops a DNA-antibody mimic platform for early detection and treatment of infectious diseases. Its technology combines computational biology, quantum chemistry, software, and machine learning to create pattern-recognition constructs.

Ananda Devices is a biotechnology company that specializes in proprietary high throughput cellular and tissue nano-organization technology. This innovative technology is designed to accelerate research and development across the pharmaceutical, food, and cosmetic industries. By enabling the innervation of various tissue types and miniaturizing existing biological models, Ananda Devices facilitates the creation of co-culture models that provide detailed access to individual components. This capability allows researchers and physicians to generate in-depth and physiologically relevant data tailored to their specific needs, thereby enhancing the efficiency and effectiveness of their research programs.

Sequegenics is a technology company that specializes in genetic analysis through its fully automated cloud platform. The company has developed a novel approach utilizing augmented low-pass long-read next-generation sequencing (NGS) to identify structural variants and other complex types of genetic variations. By processing long-read NGS raw data, Sequegenics enables clients to efficiently minimize the time and cost associated with variant calling, while also enhancing turnaround time and scalability. This innovative platform supports researchers and healthcare professionals in their efforts to better understand genetic variations, ultimately contributing to advancements in genomic medicine.

Opera Bioscience is a biotechnology company focused on providing researchers with high-quality and cost-effective reagents and recombinant proteins. The company specializes in a fermentation process that yields microbial protein products characterized by high purity levels. This innovative approach allows scientists to quickly and economically access the proteins necessary for their bioprocesses, facilitating research and development in various scientific fields. By streamlining the sourcing of essential materials such as growth factors and reagents, Opera Bioscience aims to enhance the efficiency and effectiveness of biotechnological research.

Ferrologix, founded at UCLA from Professor Dino Di Carlo's bioengineering lab, specializes in magnetic-based cell processing technology. Their core product is a unique instrument paired with disposable cartridges, capable of transporting, filtering, and organizing single cells for precise analysis or therapeutic production. Ferrologix pioneers Digital Magnetic Sorting, aiming to accelerate precision medicine research, next-generation diagnostics, and cellular therapies by offering tools that enhance efficiency and scalability in cell separation processes.

Zymvol accelerates the discovery & development of new industrial enzymes through computer simulations.

GenNext Technologies is a company that specializes in providing instrumentation, software, and services tailored for structural biology researchers in the biopharmaceutical industry. It develops advanced Protein and Contract Research Footprinting Systems, aimed at enhancing the understanding of biopharmaceutical structure, interactions, folding, aggregation, and formulation. By offering these specialized products and services, GenNext Technologies supports pharmaceutical researchers in conducting advanced studies that accelerate biopharmaceutical development, ultimately improving therapeutic efficacy and safety. The company's focus on structural biology empowers clients in the biotechnology field to advance their research efforts effectively.

Cellbox Solutions is a technology company that specializes in innovative logistic solutions for the global BioMed industry. It has developed a carbon dioxide incubator designed for the storage, isolation, handling, and analysis of biological materials. This incubator offers essential logistic services and ensures the proper handling of living cells, facilitating their storage, reproduction, transportation, and analysis. By enabling the transportation of living cells via various methods, including road, rail, and air, Cellbox Solutions supports healthcare providers in their efforts to deliver the latest therapies to patients.

CellChorus is a biotechnology company specializing in dynamic, single-cell analysis for biopharmaceutical applications. Its proprietary TIMING™ platform employs visual artificial intelligence to assess cell activation, movement, and killing over time, enhancing the understanding of cellular functions and states. By integrating insights from various analytical methods, including single-cell RNA sequencing and flow cytometry, CellChorus provides healthcare organizations with a comprehensive view of cellular phenotypes and interactions. This technology supports the development of immuno-oncology therapies and other biopharmaceutical innovations, facilitating more effective treatments through a deeper understanding of cell behavior.

Founded in Montreal, Canada in 2018, DropGenie is a biotechnology company specializing in automated genetic engineering. It offers a platform that uses microfluidics technology to miniaturize and automate complex synthetic biology workflows, enabling scientists to make changes to genomes efficiently while reducing costs and improving standardization and reproducibility.

Dalton Bioanalytics develops analytical technology that digitizes the biochemical composition of blood and translates its digital signature into actionable health insights. The platform enables monitoring of plasma analytes (proteins, lipids, electrolytes, and small molecules) through a single assay, supporting multi-omic biology to facilitate discovery, development, and delivery of precision medicine. By digitizing blood signals, the company addresses inefficiency and cost associated with traditional laboratory testing and aims to unlock comprehensive narratives about internal biology for research and clinical use.

RealSeq Biosciences specializes in advanced RNA fragmentomics technology focused on enhancing the detection of diseases to improve diagnosis and treatment. The company's innovative proprietary methods facilitate bias-free small RNA and miRNA next-generation sequencing (NGS) library construction, making their technology particularly valuable in biomarker discovery, liquid biopsy, and single-cell analysis. RealSeq's applications are primarily directed towards cancer and infectious diseases, enabling healthcare providers to enhance patient outcomes through its cutting-edge RNA-based services.

xMD Diagnostics, based in Annapolis, Maryland, specializes in the biotechnology sector, focusing on molecular diagnostics tools that enhance research and clinical laboratory practices. Formerly known as Bay Resources Development Group, the company employs advanced high-throughput microdissection technology to aid in cancer diagnosis. Its innovative tools enable the isolation and enrichment of specific cells from biopsy and other specimen samples, facilitating downstream applications such as polymerase chain reaction (PCR), genomic and proteomic analyses, next-generation sequencing (NGS), and various molecular testing methods. This technology supports pathologists, oncologists, and other medical professionals in diagnosing, monitoring, and treating patients with cancer and serious genetic diseases.

Founded in 2014, Elemental Machines is a technology company based in Cambridge, Massachusetts. It specializes in revolutionizing science-based industries by offering a smart lab platform that provides data-driven insights to enhance laboratory operations, research and development, and manufacturing outcomes.

Glyphic Biotechnologies is a biotechnology company focused on developing an advanced protein sequencing platform that aims to enhance the understanding of human biology and diseases. Recognizing that while DNA offers valuable biological insights, it is proteins that provide critical information about bodily functions, Glyphic Biotechnologies is creating a next-generation sequencing technology. This innovative platform is designed to increase binding affinity and improve consistency, ultimately facilitating the creation of personalized and precision cancer vaccines for diverse patient populations. By enabling scientists and researchers to perform single-molecule, massively parallel protein sequencing, the company aims to support the development of novel therapeutics and diagnostics, paving the way for significant advancements in biomedical research and healthcare.

Enrich Biosystems develops a microfluidics-free platform for cell imaging, analysis, and capture to advance cell-based therapies, precision medicine, and other life science applications. It provides single-cell isolation technology that operates without fluidics, using dissolvable microwells and visual enrichment strategies to simplify workflows for cell culturing, kinetics profiling, and function-based capture, enabling streamlined research and more precise study of cellular behavior.